Report of Foreign Issuer (6-k)
November 07 2017 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2017
Commission
File Number 001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation
of registrant’s name into English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On
November 7, 2017, Cellect Biotechnology Ltd. (the “Company”) announced that it will hold an Extraordinary General
Meeting of Shareholders on December 13, 2017 at 11.00 a.m. (Israel time) at the offices of the Company’s legal counsel, Doron,
Tikotzky, Kantor, Gutman, & Gross., at B.S.R. 4 Tower, 33 Floor, 7 Metsada Street, Bnei Brak, Israel. In connection with the
meeting, the Company furnishes the following documents:
|
1.
|
A
copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary
General Meeting of Shareholders describing the proposals to be voted upon at the meeting,
the procedure for voting in person or by proxy at the meeting and various other details
related to the meeting, attached hereto as Exhibit 99.1;
|
|
2.
|
A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the
meeting without attending in person, attached hereto as Exhibit 99.2; and
|
|
3.
|
A
form of Voting Instruction Card whereby holders of American Depositary Shares of the
Company may vote at the meeting without attending in person, attached hereto as Exhibit
99.3.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Cellect
Biotechnology Ltd.
|
|
|
|
Date:
November 7, 2017
|
By:
|
/s/
Eyal Leibovitz
|
|
|
Name:
Eyal Leibovitz
|
|
|
Title:
Chief Financial Officer
|
3
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2023 to Sep 2024